Download PDF
Pharmacopsychiatry 2001; 34(4): 142-146
DOI: 10.1055/s-2001-15874
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Acceptance of Pharmacotherapy for Relapse Prevention
by Chronic Alcoholics

T. Wetterling1,2 , C. Veltrup2 , K. Junghanns2 , T. Krömer-Olbrisch3 , U. Schneider3
  • 1Department of Psychiatry and Psychotherapy I, J. W. Goethe University, Frankfurt/M., Germany
  • 2Department of Psychiatry, Medical University of Lübeck, Germany
  • 3Department of Psychiatry, Medical University of Hannover, Germany
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

The willingness to take medication is a major prerequisite for compliance with biological treatment approaches in psychiatric disorders. The aim of this study was to investigate the willingness of alcoholics to improve relapse prevention using drug therapy, since there has been little information about the acceptance of such a medication as yet. 261 chronic alcoholics consecutively referred for detoxification completed a newly developed questionnaire containing items on drinking history, recent treatments, and beliefs about drug therapy for relapse prevention. In order to draw comparisons, 67 self-help group attendees and 29 alcoholics consulting an outpatient advice service were also recruited. 67.8 % of the recently detoxified alcoholics were prepared to take medication for relapse prevention, if prescribed, while 60 % the self-help group attendees refused drug therapy. There was no correlation between the acceptance of drug treatment and duration of dependence. Subjects willing to take a medication more often believed their alcoholism to be curable, and they reported a higher craving frequency. 55 % of those willing to take a medication were willing to pay for the drugs, but in most cases, at a level lower than the equivalent of 5 beers. As drug therapy acceptance is a crucial part of compliance with, and success of medical relapse prevention, our results underscore the necessity of a thorough exploration into the health beliefs of the patient and joint development of a treatment rationale prior to prescription.

References

  • 1 Allen J P, Litten R Z. Techniques to enhance compliance with disulfiram.  Alcohol Clin Exp Res. 1992;  16 1035-1041
    PubMedGoogle Scholar
  • 2 American Psychiatric Association .Diagnostic and statistical manual of mental disorders. Fourth edition. (DSM-IV). Washington; American Psychiatric Association 1994
  • 3 Brewer C. Combining pharmacological antagonists and behavioural psychotherapy in treating addictions.  Br J Psychiatry. 1990;  157 34-40
    PubMedGoogle Scholar
  • 4 DHS (German Center on Addiction Problems) .Jahrbuch Sucht 2000. Geesthacht; Neuland 1999
  • 5 Fawcett J, Clark D C, Gibbons R D, Aagesen C A, Pisani V D, Tilkin J M, Sellers D, Stutzman D. Evaluation of lithium therapy for alcoholism.  J Clin Psychiatry. 1984;  45 494-499
    PubMedGoogle Scholar
  • 6 Farmer K G. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice.  Clin Ther. 1999;  21 1074-1090
    CrossrefPubMedGoogle Scholar
  • 7 Fuller R K, Litten R Z. Drugs to decrease alcohol consumption in humans aversive agents. In: Kranzler HR (ed) The pharmacology of alcohol abuse. Berlin; Springer 1995: 369-381
    Google Scholar
  • 8 Litten R Z, Allen J P. Pharmacotherapies for alcoholism: promising agents and clinical issues.  Alcohol Clin Exp Res. 1991;  15 620-633
    PubMedGoogle Scholar
  • 9 Litten R Z, Allen J P, Fertig J. Pharmacotherapies for alcoholism: a review of research with focus on developments since 1991.  Alcohol Clin Exp Res. 1996;  20 857-876
    PubMedGoogle Scholar
  • 10 Lohse M J, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Pfaffrath D (eds) Arzneimittel-Verordnungen 2000. Berlin; Springer 2001: 557-587
    Google Scholar
  • 11 Merck K G. Sales Representative, Personal information. 
  • 12 Namkoong K, Farren C K, O'Connor P G, O'Malley S S. Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications.  J Clin Psychiatry. 1999;  60 449-453
    PubMedGoogle Scholar
  • 13 O'Malley S S, Jaffe A J, Chang G, Schottenfeld R S, Meyer R E, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence.  Arch Gen Psychiatry. 1992;  49 881-887
    Google Scholar
  • 14 O'Malley S S, Carroll K M. Psychotherapeutic considerations in pharmacological trials.  Alcohol Clin Exp Res. 1996;  20 (Suppl. 7) 17A-22A
    PubMedGoogle Scholar
  • 15 Paille F M, Guelfl J D, Perkins A C, Royer R J, Steru L, Parot P. Double-blind randomized multicentre trial of acamproste maintaining abstinende from alcohol.  Alcohol Alcohol. 1995;  30 239-247
    PubMedGoogle Scholar
  • 16 Powell B J, Penick E C, Liskow B I, Rice A S, McKnelly W. Lithium compliance in alcoholic males: a six month follow-up study.  Addict Behav. 1986;  11 135-140
    CrossrefPubMedGoogle Scholar
  • 17 Rees D W, Beech H R, More B D. Some factors associated with compliance in the treatment of alcoholism.  Alcohol Alcohol. 1984;  19 303-307
    PubMedGoogle Scholar
  • 18 Rees D W. Health beliefs and compliance with alcoholism treatment.  J Stud Alcohol. 1985;  46 517-524
    PubMedGoogle Scholar
  • 19 Saß H, Soyka M, Mann K, Zieglgänsberger W. Relapse prevention by acamprosate.  Arch Gen Psychiatry. 1996;  53 673-680
    Google Scholar
  • 20 Swift R M, Duncan D, Nirenberg T, Femino J. Alcohol patients' experience and attitudes on drug therapy for alcoholism.  J Addict Dis. 1998;  17 35-47
    CrossrefPubMedGoogle Scholar
  • 21 Volpicelli J R, Alterman A I, Hayashida M, O'Brian C P. Naltrexone in the treatment of alcohol dependence.  Arch Gen Psychiatry. 1992;  49 876-880
    Google Scholar
  • 22 Volpicielli J R, Rhines K C, Rhines J S, Volpicielli L A, Alterman A L, O'Brien C P. Naltrexone and alcohol dependence. Role of subject compliance.  Arch Gen Psychiatry. 1997;  54 737-742
    CrossrefPubMedGoogle Scholar
  • 23 Wetterling T, Kanitz R-D, Besters B, Fischer D, Zerfass B, John U, Spranger H, Driessen M. A new rating scale for the assessment of the Alcohol Withdrawal Syndrome (AWS-Scale) - as basis for a score controlled inpatient treatment.  Alcohol Alcohol. 1997;  32 753-760
    PubMedGoogle Scholar
  • 24 Wetterling T, Junghanns K, Bernzen J, Veltrup C. Medikamentöse Rückfallprophylaxe - Akzeptanz bei Alkoholkranken.  Sucht. 1999;  45 228-234
    PubMedGoogle Scholar
  • 25 Whitworth A B, Fischer F, Lesch O M, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker W W. Comparison of acamprosate and placebo in long-term treatments of alcohol dependence.  Lancet. 1996;  347 1438-1442
    CrossrefPubMedGoogle Scholar

1 In Germany, all prescribed medications costing more than DM 12 per package are paid for by the national HMO organization (AOK) or its substitutes. A package of 168 tablets of acamprosate (28 daily dosages a 6 tablets), the only available drug for relapse prevention in Germany, costs about DM 181 (DM 6,48 per day). However, the patient only has to pay DM 12 per 28 days in total, or DM 0.43 per day, and the HMO covers the main cost.

Prof. Dr. T. Wetterling

Department of Psychiatry and Psychotherapy I
Johann Wolfgang Goethe-University

Heinrich Hoffmann-Straße 10
60528 Frankfurt/Main
Germany

Phone: + 49-69-6301-4747

Fax: + 49-69-6301-5189

Email: wetterling@em.uni-frankfurt.de

      >